RMED / Catheter Precision Inc. - Arquivamentos da SEC, Relatório Anual, Declaração de Procuração

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 ☐ Transition Report Pursuant to

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of

UNSECURED CONVERTIBLE NOTE DUE [ ]1

Exhibit 10.14 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISS ION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1 933 , AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R

EXCLUSIVE AIRCRAFT DRY LEASE AGREEMENT

Exhibit 10.10 EXCLUSIVE AIRCRAFT DRY LEASE AGREEMENT This EXCLUSIVE AIRCRAFT DRY LEASE AGREEMENT, dated as of September 9, 2025 (this "Lease"), is by and between SEG JETS LLC, a Delaware Limited Liability Company (the "Lessor") and Ponderosa Air LLC a New York limited liability company (the "Lessee"). The effective date of the start of the 24 monthly lease payments will begin when actual receipt o

EXCLUSIVE AIRCRAFT DRY LEASE AGREEMENT

Exhibit 10.11 EXCLUSIVE AIRCRAFT DRY LEASE AGREEMENT This EXCLUSIVE AIRCRAFT DRY LEASE AGREEMENT, dated as of February 11, 2026 (this "Lease"), is by and between SEG JETS LLC, a Delaware Limited Liability Company (the "Lessor") and Ponderosa Air LLC a New York limited liability company (the "Lessee"). The effective date of the start of the 24 monthly lease payments will begin when actual receipt o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-CEN ☐ Form N-SAR For Period Ended: March 31, 2026 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Rea

FLEWBER GLOBAL INC. UNSECURED 10% DISCOUNT CONVERTIBLE NOTE

Exhibit 10.13 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI

SECURED PROMISSORY NOTE

Exhibit 10.9 SECURED PROMISSORY NOTE February 27, 2025 $ 365,000 FOR VALUE RECEIVED, Creatd, Inc., a Nevada corporation located at 169 Madison Avenue, Ste. 2774, New York NY 10016 (the “Borrower”), hereby promises to pay to the order of Marc Sellouk, an individual, and his successors or assignees (the “Holder”), the principal amount of Three Hundred and Sixty Five Thousand and 00/100 United States

EXCLUSIVE AIRCRAFT DRY LEASE AGREEMENT

Exhibit 10.12 EXCLUSIVE AIRCRAFT DRY LEASE AGREEMENT This EXCLUSIVE AIRCRAFT DRY LEASE AGREEMENT, dated as of March 16, 2026 (this "Lease"), is by and between SEG JETS LLC, a Delaware Limited Liability Company (the "Lessor") and Ponderosa Air LLC a New York limited liability company (the "Lessee"). The effective date of the start of the 24 monthly lease payments will begin when actual receipt of t

FLEWBER GLOBAL INC. UNSECURED SUBORDINATED PROMISSORY NOTE

Exhibit 10.15 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THIS NOTE, SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS

CATHETER PRECISION REPORTS 200% REVENUE GROWTH AND COMPLETES TRANSFORMATIVE FLYTE ACQUISITION

Exhibit 99.1 CATHETER PRECISION REPORTS 200% REVENUE GROWTH AND COMPLETES TRANSFORMATIVE FLYTE ACQUISITION Medical Device Momentum Accelerates Globally While Flyte Establishes High-Growth Aviation Platform with Immediate Revenue Traction Dramatic Reduction in Net Loss and Expanding Multi-Segment Growth Position Company for Scalable, High-Impact Expansion FORT MILL, S.C., May 18, 2026— Catheter Pre

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file numbe

CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES D CONVERTIBLE PREFERRED STOCK

Exhibit 3.2 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1. I am the Chief Financial Officer of Catheter Precision, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, of which

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2026

-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2026 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Com

CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES C-2 CONVERTIBLE PREFERRED STOCK

Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C-2 CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1. I am the Chief Financial Officer of Catheter Precision, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, of whi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2026 Catheter Precision,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2026 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 Catheter Precision, Inc.

# # # RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (in thousands) CALCULATION OF NON-CASH NUMBERS

Exhibit 99.1 Catheter Precision Reports 2025 Results and Updates on Strategic Expansion Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 – C

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.14.5 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 9, 2026, is by and among Catheter Precision, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A.    In connection with (i) the Securities Purchase Agreement by and among the parties thereto, dated

SERIES M COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC.

Exhibit 4.13 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R

DESCRIPTION OF CAPITAL STOCK

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK General The following description summarizes certain terms of our capital stock and certain provisions of our amended and restated certificate of incorporation. We have adopted an amended and restated certificate of incorporation and amended and restated bylaws, and this description summarizes certain of the provisions that are included in those documents.

Subsidiaries of Catheter Precision, Inc.

EXHIBIT 21.1 Subsidiaries of Catheter Precision, Inc. Subsidiary Jurisdiction Catheter Precision, LLC Delaware KardioNav, Inc. Nevada Cardionomix, Inc. Nevada

CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES C-1 CONVERTIBLE PREFERRED STOCK OF CATHETER PRECISION, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW

Exhibit 3.1.3C CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES C-1 CONVERTIBLE PREFERRED STOCK OF CATHETER PRECISION, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series C-1 Convertible Preferred Stock (the “Amendment”) is dated as of March 6, 2026. WHEREAS, the board of directors (the “Bo

CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES C-1 CONVERTIBLE PREFERRED STOCK

Exhibit 3.1.3B CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C-1 CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1. I am the Chief Financial Officer of Catheter Precision, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, of

SERIES M COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC.

Exhibit 4.13.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026

-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Comm

SECURITIES PURCHASE AGREEMENT

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement, dated as of March 9, 2026 (this “Agreement”), among Catheter Precision, Inc., a Delaware corporation (“Buyer”), and Creatd, Inc., a Nevada corporation (“Seller”). RECITALS WHEREAS, Buyer owns 199,800 shares of the issued and outstanding shares of common stock par value $0.001 per share (the “Common Stock”) of Fly Flyte,

CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES C-1 CONVERTIBLE PREFERRED STOCK OF CATHETER PRECISION, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW

Exhibit 10.3 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES C-1 CONVERTIBLE PREFERRED STOCK OF CATHETER PRECISION, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series C-1 Convertible Preferred Stock (the “Amendment”) is dated as of March 6, 2026. WHEREAS, the board of directors (the “Boar

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 9, 2026, is by and among Catheter Precision, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company has authorized four series of convert

CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES [C][D] CONVERTIBLE PREFERRED STOCK

Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES [C][D] CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1. I am the Chief Financial Officer of Catheter Precision, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, of

# # #

Exhibit 99.1 Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth VTAK has Agreed to Terminate its At-The-Market (“ATM”) Equity Offering Program Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation Fort Mill, SC, February 12, 2026 – Catheter Precision, Inc. (NYSE American: VTAK) (“Catheter Precisio

SERIES J EXCHANGE AGREEMENT

Exhibit 10.1 SERIES J EXCHANGE AGREEMENT THIS SERIES J EXCHANGE AGREEMENT (this “Agreement”), dated as of February 12, 2026, is entered into by and between Catheter Precision, Inc., a Delaware corporation (the “Company”), and David A. Jenkins (the “Holder”). BACKGROUND WHEREAS, the Company and the Holder are parties to that certain Debt Settlement Agreement and Release dated January 9, 2023 (the “

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2026 Catheter Precisi

-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2026 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (C

CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES J CONVERTIBLE PREFERRED STOCK

Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES J CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson does hereby certify that: 1. He is the Chief Financial Officer of Catheter Precision, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, of which

CATHETER PRECISION, INC. CERTIFICATE OF CORRECTION OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES J CONVERTIBLE PREFERRED STOCK

Exhibit 3.2 CATHETER PRECISION, INC. CERTIFICATE OF CORRECTION OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES J CONVERTIBLE PREFERRED STOCK Catheter Precision, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 103 thereof, DOES HEREBY CERTIFY: 1. The

SERIES J EXCHANGE AGREEMENT

Exhibit 10.2 SERIES J EXCHANGE AGREEMENT THIS SERIES J EXCHANGE AGREEMENT (this “Agreement”), dated as of February 12, 2026, is entered into by and between Catheter Precision, Inc., a Delaware corporation (the “Company”), and Fatboy Capital, L.P. (the “Holder”). BACKGROUND WHEREAS, the Company and the Holder are parties to that certain Debt Settlement Agreement and Release dated January 9, 2023 (t

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 6, 2026, is by and among Catheter Precision, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company has authorized four new series of

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 6, 2026, is by and among Catheter Precision, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A.    In connection with (i) the Securities Purchase Agreement by and among the parties hereto, dated a

CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES C-1 CONVERTIBLE PREFERRED STOCK

Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C-1 CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1. I am the Chief Financial Officer of Catheter Precision, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, of whi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2026

-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2026 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (C

SECURITIES PURCHASE AGREEMENT

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 6, 2026, is by and between Catheter Precision, Inc., a Delaware corporation (the “Company”) and SEG Jets LLC (the “Buyer”). RECITALS A. The Company has authorized a new series of convertible preferred stock of the Company, designated as Series D Convertible Preferred Stock, with a

CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES [C][D] CONVERTIBLE PREFERRED STOCK

Exhibit 3.2 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES [C][D] CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1. I am the Chief Financial Officer of Catheter Precision, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2025 Catheter Precision, Inc.

CATHETER PRECISION, INC. SECOND AMENDMENT TO 8% SHORT TERM PROMISSORY NOTE

Exhibit 10.2 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICTION

CATHETER PRECISION, INC. SECOND AMENDMENT TO 8% SHORT TERM PROMISSORY NOTE

Exhibit 10.3 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICTION

CATHETER PRECISION, INC. SECOND AMENDMENT TO 8% SHORT TERM PROMISSORY NOTES

Exhibit 10.1 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICTION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 Catheter Precision, Inc.

Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations Sales Revenue Up 135% over Q3 2024

Exhibit 99.1 Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations Sales Revenue Up 135% over Q3 2024 Fort Mill, SC, November 13, 2025 – Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on the cardiac electrophysiology marketplace, today reported its results of operations for the quarter and nine month

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 ☐ Transition Report Pursuant

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name

CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

Exhibit 3.1.3E CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Catheter Precision, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Catheter Precision, Inc. The original Certificate of Incorporation of the Corporation was filed with the Sec

4.2% SHORT TERM PROMISSORY NOTE DUE JULY 11, 2026 DATED JULY 11, 2025

Exhibit 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE

4.2% SHORT TERM PROMISSORY NOTE DUE JULY 11, 2026 DATED JULY 11, 2025

Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 Catheter Precision

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Catheter Precision,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Catheter Precision, Inc.

# # #

Exhibit 99.1 Catheter Precision Receives Approval for LockeT in the United Kingdom Fort Mill, SC, August 18, 2025 – Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced registration and approval in the United Kingdom for its LockeT product. LockeT is a suture ret

CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Catheter Precision, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Catheter Precision, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secret

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 Catheter Precisio

-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Catheter Precision, Inc.

Investment Banking Agreement dated February 11, 2025 entered into by and between the Company and Ladenburg Thalmann & Co. Inc.

Exhibit 10.6 Strictly Confidential February 11, 2025 Catheter Precision. Inc. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 Attention: David Jenkins, Chief Executive Officer INVESTMENT BANKING AGREEMENT Dear Mr. Jenkins: We are pleased to confirm our mutual understanding regarding the retention of Ladenburg Thalmann & Co. Inc. (“Ladenburg”) by Catheter Precision, Inc., its subsidiaries, affi

Asset Purchase Agreement dated April 22, 2025 by and between the Company and Cardionomic (assignment for the benefit of creditors), LLC

Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(a)(6) OF REGULATION S-K BECAUSE DISCLOSURE OF SUCH INFORMATION WOULD CONSTITUTE A CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. THESE OMISSIONS ARE IDENTIFIED AS [***] ASSET PURCHASE AGREEMENT EXHIBIT LIST [included for SEC filing purposes only] EXHIBIT 1 General Assignment [omitted] EXHIBIT 1.1

Amendment to Investment Banking Agreement dated as of April 16, 2025 entered into by and between the Company and Ladenburg Thalmann & Co. Inc.

Exhibit 10.1 Strictly Confidential April 16, 2025 Catheter Precision, Inc. 1670 Highway 160 West Suite 205 Fort Mill SC 29708 Attention: David A Jenkins Chief Executive Officer AMENDMENT TO INVESTMENT BANKING AGREEMENT Dear Mr. Jenkins: Reference is made to that certain Investment Banking Agreement ("Original Agreement") dated May 9, 2024, by and between Ladenburg Thalmann & Co. Inc. (''Ladenburg"

Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025 Revenue Increased 128% Year Over Year and 48% Sequentially

Exhibit 99.1 Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025 Revenue Increased 128% Year Over Year and 48% Sequentially Fort Mill, SC, AUGUST 11, 2025 – Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its results of oper

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 ☐ Transition Report Pursuant to S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of r

Up to $1,534,372 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-284217 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated May 19, 2025 (To Prospectus dated January 22, 2025) Up to $1,534,372 Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus supplement, dated May 19, 2025, to the prospectus dated January 22, 2025, filed with t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 Catheter Precision, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 Catheter Precision, Inc.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Catheter Precision, Inc.

As filed with the Securities and Exchange Commission on June 26, 2025

As filed with the Securities and Exchange Commission on June 26, 2025 Registration Statement No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Catheter Precision, Inc.

# # #

Exhibit 99.1 Catheter Precision (VTAK) Anticipates Highest LockeT Sales to Date in Q2 2025 Fort Mill, SC, June 12, 2025 – Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 202

Up to $1,895,679 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-284217 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated May 19, 2025 (To Prospectus dated January 22, 2025) Up to $1,895,679 Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus supplement, dated May 19, 2025, to the prospectus dated January 22, 2025, filed with t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Catheter Precision, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)

Placement Agent Common Stock Purchase Warrant dated June 6, 2025

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)

Placement Agent Common Stock Purchase Warrant dated June 6, 2025

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE

ARS

81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21 :DVKLQJWRQ'&   )250.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Catheter Precision, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Catheter Precision, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Catheter Precision, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

12,859,716 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-287483 PROSPECTUS 12,859,716 Shares of Common Stock This prospectus covers the offer and resale from time to time of up to 12,859,716 shares (the “Shares”) of common stock, par value $0.0001 per share, of Catheter Precision, Inc., a Delaware corporation (the “Company”), by the Selling Stockholders identified in this prospectus, including their

CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708

CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 May 28, 2025 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Margaret Sawicki Re: Catheter Precision, Inc. Registration Statement on Form S-3 File No. 333-287483 Acceleration Request Requested Date: May 30, 2025 Reques

LETTER

May 27, 2025 David A. Jenkins Chief Executive Officer Catheter Precision, Inc. 1670 Highway 160 West, Suite 205 Fort Mill, SC 29708 Re: Catheter Precision, Inc. Registration Statement on Form S-3 Filed May 21, 2025 File No. 333-287483 Dear David A. Jenkins: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding r

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Catheter Precision, Inc.

As filed with the Securities and Exchange Commission on May 21, 2025

Table of Contents As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.

Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-284217 PROSPECTUS SUPPLEMENT (to Prospectus dated January 22, 2025) $1,300,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock, par value $0.0001 per share, having an aggregate offering price of up to $1.3 million, from time to time solely through Ladenburg Thalmann & Co.

# # #

Exhibit 99.1 Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results Fort Mill, SC, May 14, 2025 – Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include:

At the Market Offering Agreement by and between the Company and Ladenburg Thalmann & Co. Inc.

Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT May 19, 2025 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Catheter Precision, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Manager”) as follows: 1. Definitions. The terms that follow, when

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Catheter Precision, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 ☐ Transition Report Pursuant to

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of

QHSLab Promissory Note dated August 10, 2021

Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

QHSLab Promissory Note dated July 19, 2022

Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

Assignment Agreement dated May 12, 2025

Exhibit 10.3 ASSIGNMENT AGREEMENT This Assignment Agreement (the "Assignment"), dated as of May 12, 2025, between Mercer Capital Global Opportunity Fund LLC (the "Assignor"), and Catheter Precision, Inc. (the "Assignee”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated May 12,

Certificate of Designation of Series B Preferred Stock.

Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, David A. Jenkins, hereby certifies that: 1. He is the Chief Executive Officer of Catheter Precision, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is aut

Form of Series L Warrant offered in May 2025.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE

Registration Rights Agreement dated May 12, 2025

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 12, 2025, between Catheter Precision, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase

Securities Purchase Agreement dated May 12, 2025

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 12, 2025, between Catheter Precision, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Catheter Precision, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file numbe

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Catheter Precision, Inc.

Asset Purchase Agreement dated April 22, 2025*

Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(a)(6) OF REGULATION S-K BECAUSE DISCLOSURE OF SUCH INFORMATION WOULD CONSTITUTE A CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. THESE OMISSIONS ARE IDENTIFIED AS [***] ASSET PURCHASE AGREEMENT EXHIBIT LIST [included for SEC filing purposes only] EXHIBIT 1 General Assignment [omitted] EXHIBIT 1.1

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 Catheter Precision, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Catheter Precision, Inc.

# # #

EXHIBIT 99.1 Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results Fort Mill, SC, March 28, 2025 – Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 an

Insider Trading Policy dated March 21, 2025

Exhibit 19.1 CATHETER PRECISION, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities (Adopted on March 21, 2025) TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violation of insider trading laws and this Policy 2 Compliance Officers 2 Reporting violations 2 Personal

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (effective 1/13/2025)

Exhibit 3.1.3.B Delaware The First State Page 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “CATHETER PRECISION, INC.”, FILED IN THIS OFFICE ON THE THIRTEENTH DAY OF JANUARY, A.D. 2025, AT 1:14 O`CLOCK P.M. AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CER

Non-plan Stock Option Award granted January 6, 2025 to Philip Anderson

Exhibit 10.31.8 Inducement Award Nonstatutory Stock Option Agreement This Stock Option Agreement (this "Agreement") is made and entered into as of January 6, 2025 by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and Philip Anderson (the "Participant"). Grant Number: NP-002 Grant Date: January 6, 2025 Exercise Price per Share: $ 0.53 Number of Option Shares: 500,000 E

Offer Letter to Philip Anderson dated January 3, 2025

Exhibit 10.31.9 January 3, 2025 CONFIDENTIAL Philip Anderson 175 Remontado Rd. PO Box 322 Boiceville, NY 12412 Dear Philip, On behalf of Catheter Precision, Inc. (the “Company” or CPI”), we are very pleased to offer you the position of Chief Financial Officer. This position reports to David Jenkins. Your targeted start date will be January 6, 2025. This is a full-time, exempt position and your sal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Subsidiaries of the Registrant

EXHIBIT 21.1 Subsidiaries of Catheter Precision, Inc. Subsidiary Jurisdiction Catheter Precision, LLC Delaware PeriKard, LLC Delaware Cardionomix, Inc. Nevada

Offer Letter to Marie-Claude Jacques dated April 24, 2024

Exhibit 10.31.10 April 24, 2024 CONFIDENTIAL Marie-Claude Jacques 151B Pleasant St. Melrose, MA 02176 Dear Marie-Claude, On behalf of Catheter Precision, Inc. (the “Company” or CPI”), we are very pleased to offer you the position of Chief Commercial Officer. This position reports to the Chief Executive Officer. Your targeted start date will be May 1, 2024. This is a full-time, exempt position and

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General The following description summarizes certain terms of our capital stock and certain provisions of our amended and restated certificate of incorporation. We have adopted an amended and restated certificate of incorporation and amended and restated bylaws, and this description summarizes certain of the provisions that are included in those documents.

Investor Presentation Dated March 2025

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Catheter Precision,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Catheter Precision, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 Catheter Precision, Inc.

Incentive Stock Option Agreement

EX-10.2 2 ex773702.htm EXHIBIT 10.2 Exhibit 10.2 Incentive Stock Option Agreement This Stock Option Agreement (this "Agreement") is made and entered into as of January 29, 2025 by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and David Jenkins (the "Participant"). Grant Number: 2023-030 Grant Date: January 29, 2025 Exercise Price per Share: $0.42 Number of Option Sha

EXHIBIT 99

EX-99 3 ex773347.htm EXHIBIT 99 EXHIBIT 99 The undersigned each hereby certifies and agrees that the above Amendment to Schedule 13D concerning securities issued by Catheter Precision, Inc. is being filed on behalf of each of the undersigned. /s/ David Jenkins Date: February 3, 2025 DAVID JENKINS FATBOY CAPITAL, L.P. By: SEACAP MANAGEMENT LLC, General Partner By: /s/ David Jenkins Date: February 3

CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708

CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 January 17, 2025 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Nicholas O’Leary Re: Catheter Precision, Inc. Registration Statement on Form S-3 File No. 333-284217 Acceleration Request Requested Date: January 22, 202

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Catheter Precision, Inc.

LETTER

January 16, 2025 David Jenkins Chief Executive Officer Catheter Precision, Inc. 1670 Highway 160 West, Suite 205 Fort Mill, SC 29708 Re: Catheter Precision, Inc. Registration Statement on Form S-3 Filed January 10, 2025 File No. 333-284217 Dear David Jenkins: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding

As filed with the Securities and Exchange Commission on January 10, 2025

As filed with the Securities and Exchange Commission on January 10, 2025 Registration No.

Proposed Form of Amendment to Certificate of Incorporation

EXHIBIT 3.2.3 CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Catheter Precision, Inc. , a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Catheter Precision, Inc. The original Certificate of Incorporation of the Corporation was filed with the Sec

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) Catheter Precision, Inc.

January 10, 2025

1670 Highway 160 West Suite 205 Fort Mill, SC 29708 USA Main: 973-691-2000 Fax: 973-691-7573 January 10, 2025 VIA EDGAR TRANSMISSION U.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2025 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive

EXHIBIT A

EXHIBIT A The undersigned each hereby certifies and agrees that the above Amendment to Schedule 13D concerning securities issued by Catheter Precision, Inc. is being filed on behalf of each of the undersigned. JENKINS FAMILY CHARITABLE INSTITUTE By: /s/ Casey A. Jenkins Date: January 3, 2025 Casey A. Jenkins, Trustee /s/ Casey A. Jenkins Date: January 3, 2025 CASEY A. JENKINS

LETTER

November 27, 2024 David Jenkins Chief Executive Officer Catheter Precision, Inc. 1670 Highway 160 West, Suite 205 Fort Mill, SC 29708 Re: Catheter Precision, Inc. Registration Statement on Form S-1 Filed November 21, 2024 File No. 333-283392 Dear David Jenkins: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regardi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive

DEFA 14A

November 21, 2024

November 21, 2024 VIA EDGAR TRANSMISSION U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street NE Washington, D.C. 20549 RE: Catheter Precision, Inc. Form S-1 Registration Statement To Whom It May Concern: On behalf of Catheter Precision, Inc. (the "Company"), we respectfully submit this Registration Statement on Form S-1 registering the resale of up to 10,695,962 shar

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Catheter Precision, Inc.

As filed with the Securities and Exchange Commission on November 21, 2024

As filed with the Securities and Exchange Commission on November 21, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition Report Pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as

# # #

EXHIBIT 99.1 Catheter Precision, Inc. Announces Third Quarter Update and Financial Results Fort Mill, SC, November 13, 2024 – Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024. Highlights of the third quarter inclu

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Catheter Precision, Inc.

VTAK / Catheter Precision, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-vtak093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Catheter Precision, Inc. (Name of Issuer) Common Stock, par value $0.0001 per shar (Title of Class of Securities) 74933X609 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch

VTAK / Catheter Precision, Inc. / INTRACOASTAL CAPITAL, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea022071814-13ga1intracathe.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Catheter Precision, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 74933X609 (CUSIP Number) September 30, 2024 (Date of Event Which

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Catheter Precision, Inc.

Form of placement agent warrant offered in October 2024

EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE

Investment Banking Agreement dated May 9, 2024

EXHIBIT 10.2 Strictly Confidential May 9, 2024 Catheter Precision, Inc. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 Attention: David A. Jenkins, Chief Executive Officer INVESTMENT BANKING AGREEMENT Dear Mr. Jenkins: We are pleased to confirm our mutual understanding regarding the retention of Ladenburg Thalmann & Co. Inc. (“Ladenburg”) by Catheter Precision, Inc. and its subsidiaries, affi

VTAK / Catheter Precision, Inc. / Jenkins Family Charitable Institute - SC 13D/A Activist Investment

SC 13D/A 1 cathetersc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Catheter Precision, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 74933X 609 (CUSIP Number) B. Joseph Alley, Jr. Arnall Golden Gregory LLP 171 17th Street NW, Suite 2100 Atlanta

Waiver Agreement Dated October 29, 2024

EXHIBIT 10.1 WAIVER AGREEMENT This Waiver Agreement is entered into between Catheter Precision, Inc., a Delaware corporation (the “Company”), and the Jenkins Family Charitable Institute, a family charitable entity formed in the state of Louisiana (the “Institute”), effective October 29, 2024. The Institute is the holder of 235,000 pre-funded warrants (the “Warrants”) of the Company which were acqu

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2024 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Catheter Precision, Inc.

Form of Series K Warrant offered in October 2024

EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE

Warrant Inducement Letter Dated October 24, 2024

EXHIBIT 10.1 CATHETER PRECISION, INC. October , 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Catheter Precision, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the Series E Common Stock Purchase Warrants (the “Series E Warrants”), Series F Common Stock Purchase Warrants (the “Series F

Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds

EXHIBIT 99.1 Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds Fort Mill, SC, October 25, 2024 – Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series E, Series F, Series G, Series H and Series I warrants (

Prospectus Supplement No. 1 Dated October 25, 2024

Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-279930 and 333-281849 Prospectus Supplement dated October 25, 2024 (To the Prospectus Dated August 29, 2024) Catheter Precision, Inc. This prospectus supplement No. 1 (“Supplement”) modifies, supersedes and supplements information contained in, and should be read in conjunction with, that certain prospectus (the “Prospectus”), dated August 29,

VTAK / Catheter Precision, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment

SC 13G 1 ea0214376-13gintracatheter.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Catheter Precision, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 74933X609 (CUSIP Number) September 3, 2024 (Date of Event Which Requires Filing of this

Exhibit 1

EX-99.1 2 ea021437601ex99-1catheter.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing

VTAK / Catheter Precision, Inc. / Jenkins Casey A. - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Catheter Precision, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 74933X 609 (CUSIP Number) B. Joseph Alley, Jr. Arnall Golden Gregory LLP 171 17th Street NW, Suite 2100 Atlanta, GA 30363 (404) 473-8500 (Name, Address

Form of Warrant Agency Agreement dated as of September 3, 2024 entered into by and between the Registrant and Equiniti Trust Company, LLC

EXHIBIT 4.5 CATHETER PRECISION, INC. and EQUINITI TRUST COMPANY, LLC (f/k/a AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC) as Warrant Agent Warrant Agency Agreement Dated as of September 3, 2024 1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of September 3, 2024 (“Agreement”), between Catheter Precision, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f

Underwriting Agreement dated as of August 30, 2024, by and between Catheter Precision, Inc. and Ladenburg Thalmann & Co. Inc., as Representative of the Underwriters (incorporated by reference to Exhibit 1.1 of Company’s Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677))

EXHIBIT 1.1 347,277 SHARES OF COMMON STOCK SERIES H WARRANTS EXERCISABLE INTO 3,120,277 SHARES OF COMMON STOCK SERIES I WARRANTS EXERCISABLE INTO 3,120,277 SHARES OF COMMON STOCK SERIES J WARRANTS EXERCISABLE INTO 3,120,277 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS EXERCISABLE INTO 2,773,000 SHARES OF COMMON STOCK OF CATHETER PRECISION, INC. UNDERWRITING AGREEMENT August 30, 2024 Ladenburg Thalma

Form of Series I Warrant offered in September 2024

EXHIBIT 4.2 SERIES I COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: 3,578,900 Issue Date: September 3, 2024 THIS SERIES I COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option

EXHIBIT 99.2 Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option FORT MILL, SC / ACCESSWIRE / September 3, 2024 / Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company, today announced the closing of its previously announced public offering of 805,900 common stock units, including 458,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2024 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commissio

Form of Pre-Funded Warrant offered in September 2024

EXHIBIT 4.4 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Catheter Precision, Inc. Warrant Shares: 2,773,000 CUSIP: 74933X 179 ISIN: Initial Exercise Date: September 3, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condi

Form of Series H Warrant offered in September 2024

EXHIBIT 4.1 SERIES H COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: 3,578,900 Issue Date: September 3, 2024 THIS SERIES H COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

Form of Series J Warrant offered in September 2024

EXHIBIT 4.3 SERIES J COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: 3,578,900 Issue Date: September 3, 2024 THIS SERIES J COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

1

EXHIBIT 99.1 Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering FORT MILL, SC / ACCESSWIRE / August 30, 2024 /Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company, today announced the pricing of its underwritten public offering of common stock units and pre-funded units for aggregate gross proceeds of approximately $3.1

347,277 Common Stock Units Each Common Stock Unit Consisting of One Share of Common Stock, One Series H Warrant to Purchase One Share of Common Stock, One Series I Warrant to Purchase One Share of Common Stock, and One Series J Warrant to Purchase On

Filed Pursuant to Rule 424(b)(1) Registration Nos. 333-279930 and 333-281849 PROSPECTUS 347,277 Common Stock Units Each Common Stock Unit Consisting of One Share of Common Stock, One Series H Warrant to Purchase One Share of Common Stock, One Series I Warrant to Purchase One Share of Common Stock, and One Series J Warrant to Purchase One Share of Common Stock 1,041,831 Shares of Common Stock Under

As filed with the Securities and Exchange Commission on August 30, 2024

As filed with the Securities and Exchange Commission on August 30, 2024 Registration No.

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Catheter Precision, Inc.

CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708

CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 August 28, 2024 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Benjamin Richie Re: Catheter Precision, Inc. Registration Statement on Form S-1 File No. 333-279930 Acceleration Request Requested Date: August 29, 2024 R

Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019

Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019 August 28, 2024 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: CATHETER PRECISION, INC. Registration Statement on Form S-1 (Registration No. 333-279930) Concurrence in Acceleration Request Ladies and Gentlemen: Ladenburg Thalm

Form of Series H Warrant offered hereby

EXHIBIT 4.15.1 SERIES H COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: Issue Date: August [], 2024 THIS SERIES H COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereo

As filed with the Securities and Exchange Commission on August 26, 2024

As filed with the Securities and Exchange Commission on August 26, 2024 Registration No.

Form of Series J Warrant offered hereby

EXHIBIT 4.15.3 SERIES J COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: Issue Date: August [], 2024 THIS SERIES J COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereo

First Amendment to Promissory Notes dated June 25, 2024, July 1, 2024 and July 18, 2024

EXHIBIT 10.33.6 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICT

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 Catheter Precision, Inc.

First Amendment to Promissory Note dated July 25, 2024

EXHIBIT 10.33.7 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICT

Form of Series I Warrant offered hereby

EXHIBIT 4.15.2 SERIES I COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: Issue Date: August [], 2024 THIS SERIES I COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereo

First Amendment to Promissory Note dated May 30, 2024

EXHIBIT 10.33.5 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICT

Form of Warrant Agency Agreement to be entered into by and between the Registrant and Equiniti Trust Company, LLC.

EXHIBIT 4.18 CATHETER PRECISION, INC. and EQUINITI TRUST COMPANY, LLC (f/k/a AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC) as Warrant Agent Warrant Agency Agreement Dated as of August , 2024 1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of August , 2024 (“Agreement”), between Catheter Precision, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f/k/a Am

First Amendment to 8% Short Term Promissory Notes Payable to FatBoy Capital, L.P.

EXHIBIT 10.1 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICTION

Form of Underwriting Agreement

EXHIBIT 1.1 COMMON STOCK UNITS EACH COMMON STOCK UNIT CONSISTING OF: ONE SHARE OF COMMON STOCK, ONE SERIES H WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK, ONE SERIES I WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK AND ONE SERIES J WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK PRE-FUNDED WARRANT UNITS EACH PRE-FUNDED WARRANT UNIT CONSISTING OF: ONE PRE-FUNDED WARRANT TO PURCHASE ONE SHARE OF COMMO

First Amendment to 8% Short Term Promissory Note Payable to David A. Jenkins

EXHIBIT 10.2 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICTION

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Catheter Precision, Inc.

First Amendment to 8% Short Term Promissory Note Payable to Jenkins Family Charitable Institute

EXHIBIT 10.3 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICTION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Catheter Precision, Inc.

# # #

EXHIBIT 99.1 Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report. Fort Mill, SC, August 14, 2024 – Catheter Precision, Inc. (NYSE American: VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Financials and Operational Report. Operational highl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report Pursuant to S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as speci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 Catheter Precision, Inc.

Promissory Note dated July 25, 2024

EXHIBIT 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 Catheter Precision, Inc.

Promissory Note dated July 18, 2024

EXHIBIT 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (filed 07/11/2024, effective 07/15/2024)

EXHIBIT 3.1 State of Delaware Secretary of State Division of Corporations Delivered 12:32 PM 07/11/2024 FILED 12:32 FM 07/11/2024 SR 20243113811 - File Number 6788771 CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Catheter Precision, Inc., a corporation organized and existing under the laws of the State of Delaware (the "Corporation"), certif

As filed with the Securities and Exchange Commission on July 12, 2024

As filed with the Securities and Exchange Commission on July 12, 2024 Registration Statement No.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2024 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commission

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2024 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commission F

Catheter Precision, Inc. (NYSE American: VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024 15% Quarter Over Quarter Growth – Initial Sales of LockeT Recorded

EXHIBIT 99.1 Catheter Precision, Inc. (NYSE American: VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024 15% Quarter Over Quarter Growth – Initial Sales of LockeT Recorded Fort Mill, SC, July 1, 2024 – Catheter Precision, Inc. (NYSE/American: VTAK) a MedTech company pioneering products in the growing field of cardiac electrophysiology, including i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 Catheter Precision, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 Catheter Precision, Inc.

Promissory Note dated July 1, 2024

EXHIBIT 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE

As filed with the Securities and Exchange Commission on June 26, 2024

As filed with the Securities and Exchange Commission on June 26, 2024 Registration No.

Promissory Note dated June 25, 2024

EXHIBIT 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Catheter Precision, Inc.

Form of Warrant Agency Agreement to be entered into by and between the Registrant and Equiniti Trust Company, LLC.

EXHIBIT 4.18 Catheter Precision, Inc. and Equiniti Trust Company, LLC (formerly known as American Stock Transfer and Trust Company), as Warrant Agent Warrant Agency Agreement Dated as of June , 2024 1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of June , 2024 (“Agreement”), between Catheter Precision, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (fo

Form of Underwriters' Warrant offered in September 2024

EXHIBIT 1.1 SHARES of Common Stock pre-funded warrants to purchase shares of common stock OF CATHETER PRECISION, INC. UNDERWRITING AGREEMENT June , 2024 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named in Schedule I hereto 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: The undersigned, Catheter Precision, Inc., a Delaware corporat

Form of Pre-Funded Warrant offered hereby

EXHIBIT 4.16 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Catheter Precision, Inc. Warrant Shares: CUSIP: ISIN: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at

Form of Underwriters’ Warrant Offered in September 2024

EXHIBIT 4.17 UNDERWRITER COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: Issue Date: , 2024 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that is si

Appendix A Description of embedded animation

Appendix A Description of embedded animation Slide 15 of the Presentation includes an embedded animation, without audio, that illustrates how VIVO works through a simulation of the user interface, including a 3D model of a patient, the patient’s heart, an EKG, and a user panel.

As filed with the Securities and Exchange Commission on June 14, 2024

As filed with the Securities and Exchange Commission on June 14, 2024 Registration No.

LETTER

United States securities and exchange commission logo June 11, 2024 David A. Jenkins Chief Executive Officer Catheter Precision, Inc. 1670 Highway 160 West, Suite 205 Fort Mill, SC 29708 Re: Catheter Precision, Inc. Registration Statement on Form S-1 Filed June 4, 2024 File No. 333-279930 Dear David A. Jenkins: This is to advise you that we have not reviewed and will not review your registration s

Quality Agreement with Zien Medical Technologies, Inc. related to LockeT Manufacture, dated March 20, 2023

EXHIBIT 10.34 Quality Agreement 1. Administrative Elements 1.1. Scope This document defines the Quality Agreement between the parties identified below. It defines the commitment between both parties to ensure that their respective products and services satisfy the quality and regulatory requirements called out in this agreement. Both parties agree to cooperate in the success of this agreement. Thi

Assignment and Agreement from David A. Jenkins in relation to LockeT dated January 24, 2023

EXHIBIT 10.28.3 ASSIGNMENT AND AGREEMENT WHEREAS, David Jenkins (hereinafter referred to singly and collectively as "ASSIGNOR") have invented a certain invention entitled "VESSEL CLOSING DEVICE", for which a U.S. Design Patent Application was filed on December 12, 2022 as Application No. 29/862,677. WHEREAS, Catheter Precision, Inc., having its principal place of business at 500 International Driv

As filed with the Securities and Exchange Commission on June 3, 2024

As filed with the Securities and Exchange Commission on June 3, 2024 Registration No.

Assignment and Agreement from Auston Locke in relation to LockeT dated July 15, 2022

EXHIBIT 10.28.2 ASSIGNMENT AND AGREEMENT WHEREAS, Auston LOCKE (hereinafter referred to singly and collectively as “ASSIGNOR”) have invented a certain invention entitled “SURGICAL VESSEL CLOSING PRESSURE DEVICE”, for which a U.S. Provisional Application was filed on February 25, 2022 as Application No. 63/314,030 and a U.S. Non Provisional Patent Application was filed on July 18, 2022 as Applicati

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Catheter Precision, Inc.

Non-plan Stock Option Award granted May 1, 2024, to Marie-Claude Jacques

EXHIBIT 10.31.7 Inducement Award Nonstatutory Stock Option Agreement This Stock Option Agreement (this "Agreement") is made and entered into as of May 1, 2024 by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and Marie-Claude Jacques (the "Participant"). Grant Number: NP-001 Grant Date: May 1, 2024 Exercise Price per Share: $ 0.5321 Number of Option Shares: 250,000 Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Catheter Precision, Inc.

Promissory Note dated May 30, 2024

EXHIBIT 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE

Invention Assignment and Royalty Agreement with Auston Locke in relation to LockeT dated May 28, 2024

EXHIBIT 10.1 Invention Assignment and Royalty Agreement This Agreement is made and entered into as of the Effective Date by and between Mr. Auston Locke, an individual residing at 4123 Costero Risco, San Clemente, CA 92673 (hereinafter “Auston”), and Catheter Precision, Inc., a corporation organized and existing under the laws of Delaware, with its principal place of business located at 1670 Highw

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Catheter Precision, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)

1

1 2

DEFA14A

ARS

ARS - PDF COPY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Catheter Precision, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Catheter Precision, Inc.

# # #

EXHIBIT 99.1 Catheter Precision, Inc. (NYSE American: VTAK) Reports Q1 2024 Highlights and Operational Performance Report. Fort Mill, SC, May 6, 2024 – Catheter Precision, Inc. (NYSE/American: VTAK) a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q1 Financials, Operational Report for the quarter ending Mar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition Report Pursuant to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as spec

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 Catheter Precision, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Catheter Precision, Inc.

# # #

EXHIBIT 99.1 Catheter Precision, Inc. (NYSE American: VTAK) Releases Operational Performance Report, Q4 and Annual 2023 Financials for Year Ending December 31, 2023 Fort Mill, SC, April 1, 2024 – Catheter Precision, Inc. (NYSE-American: VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q4 and Annual F

2023 Form of Nonstatutory Stock Option Agreement for Non-Employee Directors Under 2023 Equity Incentive Plan

EXHIBIT 10.31.3 Nonstatutory Stock Option Agreement For Non-Employee Directors This Stock Option Agreement (this "Agreement") is made and entered into as of by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and (the "Participant"). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company

Policy Relating to the Recovery of Erroneously Awarded Compensation

EXHIBIT 97 CATHETER PRECISION, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. Each Executive Officer shall be required to sign and return to the Company the Acknowledgement Form at

Notice of Stock Option Award granted March 13, 2021 to Margrit Thomassen under Old Catheter’s 2009 Equity Incentive Plan

EXHIBIT 10.31.6 Employer Copy CATHETER PRECISION, INC. 2009 EQUITY INCENTIVE PLAN NOTICE OF STOCK OPTION AWARD Unless otherwise defined herein, the terms defined in the 2009 Equity Incentive Plan shall have the same defined meanings in this Notice of Stock Option Award and the attached Stock Option Award Terms, which is incorporated herein by reference (together, the “Award Agreement”). Participan

“Description of Capital Stock,” filed as Exhibit 4.2 to our Form 10-K for fiscal year ended December 31, 2023

EXHIBIT 4.2 DESCRIPTION OF CAPITAL STOCK General The following description summarizes certain terms of our capital stock and certain provisions of our amended and restated certificate of incorporation. We have adopted an amended and restated certificate of incorporation and amended and restated bylaws, and this description summarizes certain of the provisions that are included in those documents.

2023 Form of Incentive Stock Option Agreement Under 2023 Equity Incentive Plan

EXHIBIT 10.31.5 Incentive Stock Option Agreement This Stock Option Agreement (this "Agreement") is made and entered into as of by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and (the "Participant"). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company hereby grants to the Particip

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Catheter Precision, Inc.

2023 Form of Nonstatutory Stock Option Agreement Under 2023 Equity Incentive Plan

EXHIBIT 10.31.4 Nonstatutory Stock Option Agreement For Employees This Stock Option Agreement (this "Agreement") is made and entered into as of by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and (the "Participant"). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company hereby grant

VTAK / Catheter Precision, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G 1 armistice-vtak123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Catheter Precision, Inc. (Name of Issuer) Common Stock, par value $0.0001 per shar (Title of Class of Securities) 74933X302 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 Catheter Precision, Inc.